Ag85B DNA vaccine suppresses airway inflammation in a murine model of asthma by Wu, Jian et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Respiratory Research
Open Access Research
Ag85B DNA vaccine suppresses airway inflammation in a murine 
model of asthma
Jian Wu1,2, Jun Xu3, Chuang Cai1, Xinglin Gao2, Li Li3 and Nanshan Zhong*3
Address: 1Department of Respiratory Disease, Peking University First Hospital, Beijing 100034, PR China, 2Department of Respiratory Disease, 
East District, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou 510080, PR China and 3Guangzhou Institute of 
Respiratory Disease, First Affiliated Hospital of Guangzhou Medical College, Guangzhou 510120, PR China
Email: Jian Wu - wjxst@hotmail.com; Jun Xu - xufeili@vip.163.com; Chuang Cai - skinblack1966@yahoo.com.cn; 
Xinglin Gao - gaoxinglin@hotmail.com; Li Li - lili_china@163.com; Nanshan Zhong* - nanshan@vip.163.com
* Corresponding author    
Abstract
Background: In allergic asthma, Th2 lymphocytes are believed to play important roles in orchestrating
airway eosinophilia and inflammation. Resetting the Th1/Th2 imbalance may have a therapeutic role in
asthma. The mycobacterium tuberculosis 30-kilodalton major secretory protein (antigen 85B, Ag85B) can
protect animals from M. tuberculosis infection by inducing a Th1-dominant response.
Methods: In this study, the Ag85B gene was cloned into pMG plasmids to yield the pMG-Ag85B plasmid.
The expression of Ag85B gene in murine bronchial epithelia cells was detected by Western blotting and
immunohistochemical staining after intranasal immunization with reconstructed pMG-Ag85B plasmids.
The protective effect of pMG-Ag85B plasmids immunization in airway inflammation was evaluated by
histological examination and bronchoalveolar lavage (BAL). IL-4 and IFN-g levels in the BAL and
supernatant from splenocyte culture were determined using ELISA kits.
Results: The Ag85B gene was successfully expressed in murine bronchial epithelia cells by intranasal
immunization with reconstructed pMG-Ag85B plasmids. Using a murine model of asthma induced by
ovalbumin (OVA), pMG-Ag85B immunization significantly inhibited cellular infiltration across the airway
epithelium with a 37% decrease in the total number of cells (9.6 ± 2.6 × 105/ml vs. 15.2 ± 3.0 × 105/ml, p
< 0.05) and a 74% decrease in the number of eosinophils (1.4 ± 0.2 × 105/ml vs. 5.4 ± 1.1 × 105/ml, p <
0.01) compared with the OVA-sensitized control group. There was no difference in the number of
neutrophils in BAL fluid between the pMG-Ag85B group, the OVA-sensitized control group and the empty
pMG group. IL-4 production was significantly decreased in the BAL fluid (32.0 ± 7.6 pg/ml vs. 130.8 ± 32.6
pg/ml, p < 0.01) and in the splenocyte supernatant (5.1 ± 1.6 pg/ml vs. 10.1 ± 2.3 pg/ml, p < 0.05) in the
pMG-Ag85B group compared with the OVA-sensitized control group, while IFN-g production was
increased in the BAL fluid (137.9 ± 25.6 pg/ml vs. 68.4 ± 15.3 pg/ml, p < 0.05) and in the splenocyte
supernatant (20.1 ± 5.4 pg/ml vs. 11.3 ± 3.2 pg/ml, p < 0.05).
Conclusion: In a murine model of asthma induced by OVA, intranasal immunization with pMG-Ag85B
significantly reduced allergic airway inflammation with less eosinophil infiltration. This protective effect was
associated with decreased IL-4 and increased IFN-g production in the BAL fluid and in the supernatant of
cultured splenocytes.
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Background
Allergic bronchial asthma is a complex syndrome charac-
terized by airflow obstruction, bronchial hyper-respon-
siveness and airway inflammation [1]. Elevated levels of
type 2 T cell cytokines such as IL-4, IL-5 and IL-13 are rec-
ognized as factors that initiate and accelerate allergic
inflammation in asthma. These cytokines promote IgE
synthesis, stimulate eosinophil growth and differentia-
tion, and augment mucus production. In contrast, type 1
T cell cytokines such as IL-2, IFN-g and IL-12, initiate the
clearance of viruses and other intracellular organisms by
activating macrophages and cytotoxic T cells. The two sub-
groups of helper T cells are stimulated in response to dif-
ferent immunogenic stimuli and cytokines, and constitute
an immune regulatory loop [2,3]. An imbalance between
Th1 cells and Th2 cells plays an important role in the
development of asthma [4]. Previous research revealed
that Th2 cells could provoke airway inflammation with
the restricted influence of IFN-g [5,6]. Therefore, a strat-
egy of upregulating the Th1 immune response or down-
regulating the Th2 immune response may be valuable in
the prophylaxis and management of bronchial asthma
[7,8].
It has been hypothesized that the increased prevalence of
atopy in developed countries may be associated with the
declining prevalence of some infectious diseases such as
tuberculosis [9]. Since Shirakawa [10] demonstrated an
inverse association between exposure to mycobacteria
and the subsequent development of atopy among Japa-
nese school children, mycobacterium exposure and its
relationship to asthma has gained increasing attention.
Bacille Calmette-Guérin (BCG), a live attenuated Myco-
bacterium bovis, which is commonly used in many coun-
tries as a vaccine against human tuberculosis, has been
shown to strongly induce a Th1-like response [11]. In a
murine asthma model, intranasal administration of BCG
suppressed airway eosinophilia, inflammation and airway
hyper-responsiveness, and was accompanied by decreased
Th2 cytokine levels in BAL fluid [6,12]. It has also been
reported that the BCG vaccine had a protective effect in
young children against the development of allergic symp-
toms [13,14]. A series of animal model studies demon-
strated that various preparations of mycobacterial
antigens possessed prophylactic effects on antigen
induced airway inflammation [6,12,15,16].
The 30-kDa major secretory protein (Ag85B) is the most
abundant protein of M. tuberculosis, and is a potent
immuno-protective antigen as well as a leading drug tar-
get [17,18]. Immunization with Ag85B DNA [19-22] or
purified Ag85B protein [18] induced a strong antigen-spe-
cific CD4+ T cell and IFN-g response and protected
against TB [23]. More recently, it was shown that Ag85B
immunization inhibited acute phase atopic dermatitis
[24]. Our previous study demonstrated that, in vitro,
Ag85B could enhance the Th1 response in cultured
PBMCs from mite-allergic asthma patients [25]. We
hypothesized that the intranasal administration of Ag85B
DNA might suppress asthmatic airway inflammation by
enhancing the Th1 immune response. In this study, recon-
structed pMG-Ag85B DNA was intranasally administrated
into C57Bl/c mice and inhibited airway inflammation in
OVA-sensitized/challenged mice.
Methods
Animals
C57Bl/c mice were purchased from the animal center of
First Military Medical University (Guangzhou, China). All
animals were maintained under specific pathogen-free
conditions. Experiments were conducted following the
University guidelines for the care and use of laboratory
animals.
Plasmid construction
The Ag85B gene was amplified from the plasmid pMTB30,
which was kindly provided by M. A. Horwitz and G.
Harth, UCLA. The 5' primer (5'-ggaggatccggcacaggtatgaca-
gacgtgagcc-3') contained a BamH I restriction site and was
annealed to nucleotides -9 to +16 relative to the A residue
of the initiator methionine codon ATG. The 3' primer (5'-
taagtctagattcggttgatcccgtcagccgg-3'), located downstream
of the stop codon, contained a Xba I restriction site and
was annealed to nucleotides +992 to +971 relative to the
initiator methionine codon ATG. The gene for Ag85B was
cloned into pMG plasmids (InvivoGen, San Diego, Cali-
fornia, USA) to yield the pMG-Ag85B plasmid. The clone
was sequenced by double-stranded sequencing (Sangon
Scientific Co. Shanghai, China). Endotoxin-free plasmid
DNA was prepared and purified with the Qiagen Endo-
toxin-free Plasmid Maxi Kit (Qiagen, GmbH, Hilden).
Detection of Ag85B mRNA expression by RT-PCR
Total RNA was isolated using TRIzol reagent from mice
lung tissues immunized with Ag85B DNA. First-strand
cDNA synthesis and PCR were performed using standard
procedures. The sequences of the forward and reverse
primers of pMG-Ag85B and b-actin were as follows:
Ag85B: 5'-ggaggatccggcacaggtatgacagacgtgagcc-3' and 5'-
taagtctagattcggttgatcccgtcagccgg-3'; b-actin: 5'-tcatgccatcct-
gcgtctggacct-3' and 5'-cggactcatcgtactcctgcttg-3'.
Detection of Ag85B protein expression by Western 
blotting and immunohistochemistry
The supernatant of transfected murine bronchial epithe-
lial cells was collected and condensed. Samples (20 mg of
protein) underwent electrophoresis on a SDS-PAGE gel.
Proteins bands were probed with Ag85B antibodies.
Ag85B standard protein (100 ng) was the positive control.
Ag85B protein expression in vivo was detected using
immunohistochemistry staining. Lung tissue sectionsRespiratory Research 2009, 10:51 http://respiratory-research.com/content/10/1/51
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were then incubated with 3% H2O2 for 10 minutes, block-
ing buffer (0.1 M phosphate buffer containing 1% BSA
and 10% normal goat serum) for 10 min at room temper-
ature and the primary anti-Ag85B antibody overnight at
4°C. The monoclonal antibodies were raised in female
New Zealand White rabbits against a purified 30 kDa pro-
tein (Ag85B). Anti-rabbit biotinylated antibody was
added at room temperature followed by avidin-horserad-
ish peroxidase conjugate.
Intranasal immunization
OVA solution was made by mixing 20 mg OVA (Sigma
Chemical Co., Louis, Missouri, USA) with 2 mg alum in
100 ml saline. All of the mice were anaesthetized with 50
mg/kg pentobarbital sodium. Mice in the three groups,
except for normal control group, then intraperitoneally
injected with 100 ml OVA solution on days 0, 7 and 14. On
days 21 and 28, mice were grouped and immunized with
100 mg of endotoxin-free pMG-Ag85B plasmids, empty
pMG or saline. The three groups were then intranasally
administered 200 mg OVA on days 42, 43 and 44. On the
following 2 days, mice were exposed to nebulized 1%
OVA for 30 min. Mice sensitized and challenged with
OVA, treated with saline during the resting phase served as
OVA-sensitized control. Mice always treated with saline
served as normal control group.
Bronchoalveolar lavage and histopathological 
examination
Mice were sacrificed 24 hours after the last OVA treatment.
In each group, seven animals were used for BAL fluid and
another six for lung histopathological examination. After
retro-orbital bleeding under anesthesia, lungs were lav-
aged three times with 0.8 ml PBS and the BAL fluid was
collected. The supernatants were removed and stored at -
20°C. Cell pellets were resuspended in 1 ml PBS and total
cells were counted with a hematocytometer. For his-
topathological examination, the right and left lungs were
sectioned from top to bottom, with four-to-five cross-sec-
tional pieces taken from each lung.
Splenocyte culture
Mouse spleens were harvested, minced and filtered
through a fine nylon mesh. Red blood cells were removed
using ACK lysing buffer (Invitrogen Life Technologies).
Cells were then incubated in RPMI-1640 medium (Gibco
BRL) supplemented with 10% fetal calf serum, 2 mM L-
glutamine and antibiotics. Supernatants were collected
after incubation for 96 hours.
Enzyme-linked immunosorbent assay (ELISA) for cytokine 
production
IL-4 and IFN-g levels in BAL fluid and the supernatant of
cultured splenocytes were determined using ELISA kits
(R&D Systems). The assay inter-well variances were <10%
for cytokine concentrations ranging 5–10 pg/ml.
Statistical analysis
Data are presented as means ± SD. Unpaired two-tailed
Student's t-test was used to determine significant differ-
ences between groups.
Results
Expression of the Ag85B gene
The Ag85B expression vector, pMG-Ag85B was con-
structed by inserting a 992-bp Ag85B gene into the XBal I
and BamHI sites of the pMG vector. Transfection was con-
firmed by restriction enzyme digestion, PCR and sequen-
tial analysis (data not shown). Ag85B mRNA was detected
in murine bronchial epithelial cells 36 hours after trans-
fection with endotoxin-free pMG-Ag85B plasmids, but
not in pMG plasmid-transfected cells (Fig. 1A). Ag85B
protein was also detected in the supernatant of the pMG-
Ag85B-transfected cells using Western blotting (Fig. 1B).
We then examined Ag85B gene expression in vivo. Ag85B
mRNA was detected in lung tissue 36 hours after the sec-
ond intranasal immunization with pMG-Ag85B. Immu-
nohistochemical staining revealed that the Ag85B gene
was mainly expressed in bronchial epithelial cells, bron-
chiolar submucosa and alveolar epithelial cells (Fig. 1D).
Immunization with pMG-Ag85B DNA protected mice from 
airway eosinophilic inflammation
Since Ag85B was successfully expressed in vivo, we won-
dered whether Ag85B could protect mice from the devel-
opment of asthma. We used the OVA sensitization/
challenge asthma model. In this model, mice were intra-
peritoneally injected with high doses of OVA protein once
a week for 3 weeks, rested for 4 weeks, and then chal-
lenged with OVA through the airway. These mice devel-
oped serious inflammation in the lung compared with the
saline-treated mice, mimicking the pathological process
of asthma. In this study, during the resting phase, mice
were intranasally immunized twice with pMG-Ag85B
plasmid DNA, empty pMG or saline. All mice were then
challenged with 1% OVA through the airway except the
saline group and lung inflammation was examined 24
hours later (Fig. 2A). In the OVA-sensitized control group,
histological examination revealed shedding of the airway
epithelium and swelling of the bronchiolar wall with cel-
lular infiltration, particularly in the parabronchiolar and
perivascular area (Fig. 2B, upper right). However, pMG-
Ag85B immunization greatly inhibited cellular infiltra-
tion across the whole area (Fig. 2B, lower right). No
inflammation was observed in the saline group (Fig. 2B,
upper left). Consistent with the histological data, the total
number of cells and the number of eosinophils in the BAL
fluid was significantly increased in the OVA-sensitized
control group compared with the saline group (Fig.Respiratory Research 2009, 10:51 http://respiratory-research.com/content/10/1/51
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2C&2D). In the pMG-Ag85B group, OVA-induced inflam-
mation was suppressed with a 37% decrease in the total
number of cells (9.6 ± 2.6 × 105/ml vs. 15.2 ± 3.0 × 105/
ml, p < 0.05) and a 74% decrease in the number of eosi-
nophils (1.4 ± 0.2 × 105/ml vs. 5.4 ± 1.1 × 105/ml, p <
0.01) compared with the OVA-sensitized control group.
There were no significant differences in the total number
of cells or number of eosinophils between the empty pMG
group and the OVA-sensitized control group (Fig.
2C&2D). There was no significant difference in the
number of neutrophils in BAL fluid between the pMG-
Ag85B group, the OVA-sensitized control group and the
empty pMG group (pMG-Ag85B: 2.2 ± 0.4 × 105; OVA-
sensitized control: 2.5 ± 0.5 × 105 cells; pMG: 2.3 ± 0.5 ×
105; p > 0.05), while the number of neutrophils in BAL
fluid was significantly increased in the three test groups
compared with that in the normal control group (normal
control group: 0.8 ± 0.1 × 105 cells; all p < 0.05)
Cytokine production in BAL fluid and splenocytes after 
pMG-Ag85B immunization
Previous studies revealed an imbalance between Th1 and
Th2 cells in asthma models. This phenomenon was con-
sidered an important pathogenic mechanism of asthma.
We wondered whether the cytokine profile was reversed
by pMG-Ag85B immunization in the asthma model dur-
ing the protective process.
BAL fluid was collected 24 hours after the last OVA chal-
lenge. Splenocytes were cultured and the supernatant was
obtained at 96 hours. Levels of IL-4 and IFN-g were tested
Ag85B expression in murine bronchial epithelial cells Figure 1
Ag85B expression in murine bronchial epithelial cells. 
A. Murine cells were transfected with pMG plasmids (Lane 1) or 
pMG-Ag85B plasmids (Lane 2). Ag85B mRNA (992 bp) expres-
sion was tested 36 hours after transfection by RT-PCR. B. As 
described in A, Western blotting was used to determine Ag85B 
protein expression in the supernatant of pMG-Ag85B trans-
fected murine bronchial epithelial cells (Lane 1) and pMG trans-
fected cells (Lane 2). The positive control was 100 ng purified 
Ag85B protein (Lane 3). C, D: Mice were intranasally immunized 
with 100 mg pMG (C) or pMG-Ag85B plasmids (D), with a 
booster dose 7 days after the initial immunization. Immunohis-
tochemistry staining shows Ag85B protein expression in the 
lung 48 hours after the booster dose.
Immunization with pMG-Ag85B inhibited inflammatory cell  infiltration in the lung Figure 2
Immunization with pMG-Ag85B inhibited inflamma-
tory cell infiltration in the lung. A. Timing of the sensiti-
zation, immunization and challenge (NS = normal saline). B. 
Lung tissue was taken 24 hours after the last OVA challenge. 
H&E staining of lung sections from the normal (upper left), 
OVA (upper right), empty pMG (lower left) and pMG-Ag85B 
(lower right) groups. n = 6 mice per group. C, D. BAL fluid 
was collected 24 hours after the last OVA challenge. The 
total number of cells (C) and number of eosinophils (D) 
were counted. Values are means ± SD for seven animals. *P 
< 0.05, **P < 0.01, for the pMG-Ag85B group versus the 
OVA-sensitized control group; +P < 0.05, ++P < 0.01, for 
the pMG-Ag85B group versus the pMG group (unpaired 
two-sided Student's t-test).Respiratory Research 2009, 10:51 http://respiratory-research.com/content/10/1/51
Page 5 of 8
(page number not for citation purposes)
using ELISAs. In the OVA-sensitized control group, IL-4
production in the BAL fluid was 5-fold higher than in the
saline group (Fig. 3A) and 2-fold higher in the splenocyte
supernatant (Fig. 3B). However, in the pMG-Ag85B
group, IL-4 production was significantly decreased both in
the BAL fluid (32.0 ± 7.6 pg/ml vs. 130.8 ± 32.6 pg/ml, p
< 0.01) and in the splenocyte supernatant (5.1 ± 1.6 pg/
ml vs. 10.1 ± 2.3 pg/ml, p < 0.05) compared with the
OVA-sensitized control group. In addition, pMG-Ag85B
immunization increased IFN-g production both in the
BAL fluid (137.9 ± 25.6 pg/ml vs.68.4 ± 15.3 pg/ml, p <
0.05) and the splenocyte supernatant (20.1 ± 5.4 pg/ml
vs. 11.3 ± 3.2 pg/ml, p < 0.05) (Fig. 3C&3D).
Discussion
Bronchial epithelial cells (BECs) are known to play an
integral role in the airway defense mechanism, which
involves the mucociliary system as well as mechanical
barriers. BECs also interact with immune and inflamma-
tory cells by direct adhesion as well as by humoral factors
including cytokines, and may play a crucial role in
mucosal immunity [26]. In the present study, the Ag85B
gene was successfully expressed in murine BECs after
transfection with the pMG-Ag85B plasmid. Mice with
repeated OVA sensitization and aerosol challenge mim-
icked human allergic asthma. Intranasal administration
of Ag85B DNA significantly inhibited airway eosi-
nophilia with a 74% decrease in number of eosinophils
in BAL fluid and attenuated eosinophilic airway inflam-
mation. The inhibitory effect was associated with
increased IFN-g  levels and decreased IL-4 levels in BAL
fluid and in the supernatant of cultured splenocytes.
These results are consistent with previous studies in
which BCG was administered by the nasal route in
murine allergic rhinitis [27] or in asthma models
[6,12,28]. In addition, intranasal administration or
direct instillation into the trachea are easier to reach
[26]. They have been shown to be the most effective
routes in reversing antigen-induced asthma symptoms,
BAL and peribronchial eosinophilia, and BAL fluid IL-5
levels [29]. These routes were also superior to the intra-
peritoneal or subcutaneous routes [6]. Our data support
the notion that Th2 cytokines are involved in Ag-induced
allergic responses. We also provide the first in vivo evi-
dence that an Ag85B DNA vaccine inhibits OVA-induced
airway inflammation. This inhibitory effect was associ-
ated with the switch from Th2 cytokine production to
Th1 cytokine production in the lung and at the systemic
level. These data are in accordance with recently reported
results from studies that used noninvasive mucosal exog-
enous gene delivery in mice models of asthma. IL-18, IL-
12 and IFN-g  gene-expressing plasmids or transferred by
an adenovirus vector [30-32] can prevent and reverse
established allergen-induced airway hyper-reactivity, air-
way eosinophilia and Th2 cytokine production. Our pre-
vious in vitro study showed that the supernatant from
cultured murine BECs transfected with Ag85B DNA plas-
mids up-regulated IFN-g  levels in peripheral blood
mononuclear cells from mite-allergic asthmatic patients
[25]. Therefore, our studies and other previous studies
suggested that BECs are a promising target for intranasal
Th1 modulator genes in the management of allergic pul-
monary disease, and that intranasal administration is a
safe, efficient and noninvasive mucosal route of treat-
ment against allergic asthma [33].
A large quantity of data obtained from human and animal
models demonstrated that BCG vaccine and other myco-
bacteria have preventive and therapeutic effects on atopic
diseases such as allergic asthma [6,12-16]. But, there
seems to be a discrepancy. Factors such as timing of vacci-
nation, the route of delivery, genetic contribution and eth-
nicity, and dose and strain differences, could be
responsible for the discrepancies that have been observed
[34]. Furthermore, inoculation with BCG in humans can
only be performed by intradermal administration, and
may induce more adverse reactions including suppurative
Cytokine production in the BAL fluid and spleen after pMG- Ag85B immunization Figure 3
Cytokine production in the BAL fluid and spleen 
after pMG-Ag85B immunization. Mice were sensitized 
with OVA 3 times, and administered with pMG-Ag85B plas-
mid DNA, and then challenged with OVA. BAL fluid and 
spleens were harvested 24 hours after the last OVA chal-
lenge. IL-4 (A) and IFN-g (C) levels in the BAL fluid were 
measured directly. Splenocytes were cultured and IL-4 (B) 
and IFN-g (D) in the culture supernatant were measured 96 
hours after incubation. Results are expressed as means ± SD 
for seven animals. *P < 0.05, **P < 0.01, for the pMG-Ag85B 
group versus the OVA-sensitized control group; +P < 0.05, 
++P < 0.01, for the pMG-Ag85B group versus the pMG 
group.Respiratory Research 2009, 10:51 http://respiratory-research.com/content/10/1/51
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lymphadenitis, local abscess, and anaphylaxis during vac-
cination [35]. Repeated BCG injections in asthmatic
patients showed no efficacy on markers of asthma severity
in addition to excessive local reactions to BCG [36]. Thus,
these limitations have limited the use of BCG in asthma.
Ag85B consists of a few specific molecules and is the most
abundant extracellular protein expressed by Mycobacteria
or BCG. In addition, it can be delivered by intranasal or
intramuscular injection [19,21]. Therefore, it can be
expected to be safer with a lower incidence of adverse
events compared with BCG for protecting mice against TB
[18] or atopic disease.
The mechanism of Ag85B immunization against TB
infection is relative to the attenuation of the Th2 cell-
mediated immune response and increased IFN-g  pro-
duction [27]. The mechanism of Ag85B immunization
against asthma is unclear. However, it might be due to
increased IFN-g  production. IFN-g  was suggested to sup-
press pulmonary eosinophilia via the following path-
ways: first, by blocking IL-4, thus down-regulating the IL-
12 receptor pathway and leading to development of T
cells restricted to the Th1 phenotype; second, by activat-
ing highly phagocytic macrophages and preventing air-
way allergens from entering the submucosal sites
containing the professional antigen-presenting cells and
sensitized T cells [28]; and third, by inhibiting chemok-
ines (for instance, eotaxin) and CC chemokine receptor
3 (CCR3) expression during allergic inflammation
[1,29]. These are essential for eosinophil homeostasis
and infiltration by Th2 cells, and thus suppress the devel-
opment of an atopic phenotype. Furthermore, it is possi-
ble that Mycobacterial major secretary proteins, such as
Ag85B, can generate regulatory T cells [37] and reverse
allergic diseases. It has been shown that Ag85B DNA
immunization can prevent and treat atopic dermatitis
through the induction of Foxp3+ T regulatory (Treg) cells
[24]. Several studies have shown that Mycobacterial lipo-
proteins [38] or mycobacterium vaccae [39] bind to den-
dritic cells and macrophage-bound Toll-like receptors
(TLRs) and this interaction leads to the prominent syn-
thesis of IL-12, and thus induces protective Th1 immu-
nity with an increase in the number of Treg cells, which
also controls IgE antibody production. However, it
remains to be elucidated whether Ag85B triggers Treg
cells in addition to eliciting strong protective Th1
immune responses. In addition, intranasal administra-
tion of the Ag85B DNA vaccine after exposure to OVA is
a form of mucosal immunotherapy. The immune system
in the aerodigestive mucosa maybe induce immune tol-
erance rather than immunostimulation and then
decrease the airway eosinophilic inflammation [33]. In
preclinical models, T-cell anergy, a decrease in the Th2
response, and an induction of TGF-b- and IL-10-produc-
ing regulatory T cells have been proposed to be potential
mechanisms for immune tolerance through the nasal
route [40,41].
In this study, we found that OVA-induced airway inflam-
mation was inhibited after Ag85B vaccine treatment;
meanwhile, Th1 cytokine production was increased while
the Th2 cytokine production was decreased in the lung
and spleen. However, it was unclear whether the inflam-
matory inhibition was due to the direct effect of the vac-
cine or the Th1-biased response. Moreover, the Ag85B
vaccine might drive T cells to switch into Th1 cells, which
subsequently suppress airway inflammation by Th1
cytokine production. To investigate the mechanism, fur-
ther studies of the effect of the Ag85B vaccine are required
using IFN-g -/- or IL-4-/- mice. In addition, more studies of
Treg cells are needed to evaluate the inhibition of eosi-
nophil recruitment in the lung and other asthmatic symp-
toms, and to determine the critical roles of the Th1 and
Th2 cytokines in mediating these effects.
Conclusion
In summary, we have described a novel approach of intra-
nasal administration of Ag85B DNA to inhibit eosi-
nophilic airway inflammation induced by OVA
sensitization. This was associated with down-regulation
of Th2 cytokines and up-regulation of Th1 cytokines. Fur-
ther studies are needed to investigate the effect of Ag85B
DNA on bronchial hyper-responsiveness and Treg cells.
Because intranasal administration of Ag85B gene is non-
invasive, effective and can be easily modified, it offers a
promising method for the development of DNA vaccines
to asthma.
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